The study's objective was to determine the frequency of skin manifestations in patients on chemotherapy. This cross-sectional study was conducted on 170 patients on chemotherapy with post-acne scarring and hyperpigmentation not responsive to other treatments were included at the Department of Dermatology, Unit-1, Jinnah Hospital Lahore from April 2016 to September 2016. Patients of both genders and any age and on chemotherapy, at least after their first dosage, were included. Patients having skin manifestation before chemotherapy, patients with a history of HCV, those having diabetes mellitus (Fasting BSR > 100 mg/dl), andpatients having other connective tissue diseases, SLE, DLE, etc., were excluded. A dermatologic examination was performed, and biopsy, mycological and bacteriological tests were conducted if necessary. Skin manifestations were labelled. A total of 170 chemotherapy patients participated in this trial. There were 58 (34.1 percent) females and 112 (65.9%) males. Fifty-three people (31.2%) had no skin manifestations, 61 people (34.9%) had one, 40 people(23.5%) had two, and 16 people (9.4%) had three skin manifestations. A total of 75 patients (44.1%) are under the age of 30, 40 patients (23.5%) are between the ages of 31 and 45, and 55 patients (32.4%) are over the age of 45. In 2 cases, acral erythema was seen (1.2 percent ). In 21 cases, dry skin was seen (12.4 percent ). There was alopecia in 93 individuals (54.7 percent ). Sixteen patients still had the eruption (9.4 percent ). Three of the patients had acne(1.8 percent ). In 7 cases, purpura was present (4.1 percent ). In 47 cases, mucositis was found (27.6 percent ). Age and gender had no impact on the number of cutaneous manifestations. People receiving chemotherapy frequently get cutaneous symptoms. Alopecia, mucositis, and xerosis were among the most typical cutaneous signs.
The most effective systemic therapy for acne is Isotretinoin. However, Isotretinoin has many side effects, including known side effects like dryness, palmoplantar exfoliation, rash, teratogenicity, raised intraocular pressure, and deranged liver functions and lipid profile. Its lesser-known side effects include its effects on platelet count and mean platelet volume (M.P.V.). This Quasi-experimental case series was conducted to observe the change in platelet count and mean platelet volume in patients taking Isotretinoin for acne vulgaris, attending the dermatology outpatient department at Jinnah Hospital Lahore from May 10th 2016 to November 9th 2016. After ethical committee approval and informed consent, subjects of acne vulgaris with an indication for Isotretinoin were included in the study from O.P.D. Relevant demographic and clinical details were recorded in a standardized predesigned proforma. Citrated blood samples were taken under aseptic conditions. Baseline platelet counts and mean platelet volume were determined using an auto-analyzer in the pathology laboratory of Jinnah hospital Lahore. All the patients were advised to take daily Isotretinoin at a dose of 0.5 mg/kg for 12 weeks. Platelet counts and mean platelet volume were again measured after twelve weeks after the start of treatment. A total of 100 patients completed the study. The age of the patients ranged from 18 to 60 years with a mean + sd age of 27.26+5.88 years. Out of these 41%(n=41) were male and 59%(n=59) were females. The severity of acne was measured using Global Acne Grading System (G.A.G.S.). It was recorded that 62%(n=62) had moderate, 22%(n=22) had severe while 16%(n=16) had very severe acne vulgaris. The mean pre-treatment platelet count was 271273+9139 c/µL, while 259192+11717 c/µL was post-treatment. The mean difference was 12080+8140 c/µL, and the p-value was 0.001. The mean platelet volume was 10.63+1.01 fl as pre-treatment and 9.77+1.01 fl as post-treatment. The mean difference was 0.85+0.04 fl, and the p value was 0.001. We concluded that Isotretinoin decreases platelet count and means platelet volume in patients receiving isotretinoin treatment for acne vulgaris.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.